Abstract 340P
Background
The optimal follow-up strategy for the detection of relapse in patients with diffuse large B-cell lymphoma (DLBCL) has not been clarified. In this report, we assess the role of laboratory tests and CT for surveillance and investigate the risk factors for recurrence.
Methods
We reviewed the clinical records of patients who achieved CR by PET-CT after received R-CHOP like regimen in our hospital for DLBCL between February 2008 and February 2022. Clinical evaluation post treatment was done every 3-6 months in the first 2 years, and every 6–12 years in the 3 coming years.
Results
A total of 324 patients were eligible for inclusion in this study. The median duration of follow-up for surviving patients was 4.3 years. The cumulative incidence of relapse without death at 2 and 5 years was 13.3% and 21.6%. Overall, 1453 CT scans were carried out through surveillance. The total of 64 patients relapsed within the observation period. Of these, 19 patients were detected to have recurrence on surveillance CT scans. On univariate analysis, ABC-type, extranodal (EN) stites > 1 at diagnosi, and relative dose intensity (RDI) < 90% were risk factors for recurrence. On Fine-Gray regression analysis, ABC-type (HR 2.1, 95% confidence interval [95% CI] 1.1-3.7. p=0.018) and EN sites > 1 at diagnosis (HR 1.8, 95% CI 1.1-3.6. p=0.031) were independent risk factors for recurrence. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the surveillance value of soluble interleukin-2 (sIL-2R) (HR 0.81, 95% CI 0.72–0.90) was significantly larger than lactate dehydrogenase (LDH) (0.65, 95% CI 0.55–0.75. p=0.024). While in the normal pretreatment sIL-2R group, the AUC of the ROC curve of sIL2R was small (0.57), however, in the high pretreatment sIL-2R group, the AUC of the ROC curve of sIL2-R (0.83, 95% CI 0.74-0.91) was high. We defined the best cutoff value of the sIL2-R as 607.5 using a ROC curve in the high pretreatment sIL-2R group (Sensitivity 0.63. Specificity 0.88).
Conclusions
Routine surveillance CT scans were of limited value in detecting asymptomatic relapse. ABC-type and EN sites were independent risk factors for recurrence. The measurement of sIL-2R might be useful for surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract